<SEC-DOCUMENT>0001144204-14-072687.txt : 20141208
<SEC-HEADER>0001144204-14-072687.hdr.sgml : 20141208
<ACCEPTANCE-DATETIME>20141208083825
ACCESSION NUMBER:		0001144204-14-072687
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20141208
FILED AS OF DATE:		20141208
DATE AS OF CHANGE:		20141208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36000
		FILM NUMBER:		141271066

	BUSINESS ADDRESS:	
		STREET 1:		XTL BIOPHARMACEUTICALS LTD
		STREET 2:		C/O ALSTON & BIRD LLP, 90 PARK AVENUE
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		972 9 955 7080

	MAIL ADDRESS:	
		STREET 1:		85 MEDINAT HAYEHUDIM ST.
		STREET 2:		PITUACH, PO BOX 4033
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			46140
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v396033_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Rule 13a-16 or 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of December, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: <B>000-51310</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>&#9;<B>XTL Biopharmaceuticals Ltd.&#9;</B></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name
into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>85 Medinat Hayehudim St., Herzliya </B><BR>
<B>Pituach, PO Box 4033,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>____________<U>Herzliya 4614001, Israel</U>____________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal
executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT>&#9;Form 40-F&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;No&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2(b): 82-<U> N/A </U>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Incorporation by Reference: This Form
6-K of XTL Biopharmaceuticals Ltd. dated December 8, 2014 is hereby incorporated by reference into the registration statements
on Form S-8 (File No. 333-148085, File No. 333-148754 and File No. 333-154795) filed by XTL Biopharmaceuticals Ltd. with the Securities
and Exchange Commission on December 14, 2007, January 18, 2008, and October 28, 2008, respectively.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Re: Change in Director Positions </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 5, 2014, the board of directors
(the &ldquo;Board&rdquo;) of XTL Biopharmaceuticals Ltd. (the &ldquo;Company&rdquo;) approved the appointment of Dr. Jonathan Schapiro
and Dr. Dobroslav Melamed to the Board to serve until the General Meeting of Shareholders on December 30, 2014, where they will
be nominated for election by the shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 8, 2014, the Company issued
a press release announcing the appointments. A copy of the press release is being filed as Exhibit 99.1 to this report and incorporated
herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following exhibit
is filed as part of this report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify"><B>Exhibit <BR>
<U>Number</U></B></TD>
    <TD STYLE="width: 88%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Description</U></B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify">99.1</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify">Press Release dated December 8, 2014.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About XTL Biopharmaceuticals Ltd. (&ldquo;XTL&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">XTL
Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on the acquisition and development of pharmaceutical products for
the treatment of unmet clinical needs. XTL is focused on late stage clinical development of drugs for the treatment of multiple
myeloma, schizophrenia and lupus. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white">XTL
is a public company traded on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel-Aviv Stock Exchange (TASE: XTL). XTL shares
are included in the following indices: Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Bluetech-50.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor Contacts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jeffrey Goldberger / Garth Russell</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">KCSA Strategic Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: 212-896-1249 / 212-896-1250</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email: jgoldberger@kcsa.com / grussell@kcsa.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cautionary Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of the statements included in this
Form 6-K may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the
protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>XTL BIOPHARMACEUTICALS LTD.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; width: 30%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; width: 24%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; width: 23%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0; width: 23%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: December 8, 2014</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By: <U>/s/
    Josh Levine&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 0 0.25in; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Josh Levine</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 0 0.25in; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; padding: 0; text-decoration: underline; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>Exhibit Number</U></B></FONT></TD>
    <TD STYLE="width: 85%; padding: 0; text-decoration: underline; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>Description</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Press Release dated December 8, 2014.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v396033_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>XTL Biopharmaceuticals Appoints Dr. Jonathan
Schapiro MD and Dr. Dobroslav Melamed to<BR>
 the Board of Directors to Help Lead Development of its Clinical Assets </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>HERZLIYA, Israel</B> &ndash; December 08, 2014 &ndash; XTL
Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) (&ldquo;XTL&rdquo; or the &quot;Company&quot;), a clinical-stage biopharmaceutical
company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical
needs, announced today that the Board of Directors has appointed two new members, Dr. Jonathan Schapiro and Dr. Dobroslav Melamed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Josh Levine, Chief Executive Officer of XTL, stated, &ldquo;Both
new Directors bring a wealth of experience in the clinical development of pharmaceutical products and will contribute significantly
to the Company&rsquo;s efforts to develop and capitalize on its two lead programs: hCDR1 for the treatment of SLE (lupus) and EPO
for the treatment of multiple myeloma.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Jonathan Schapiro, 54, is currently an Adjunct Clinical
Assistant Professor in the Department of Medicine, Division of Infectious Diseases and Geographic Medicine at Stanford University
School of Medicine and a Director of HIV/AIDS at the National Hemophilia Center at Sheba Medical Center in Tel Aviv, Israel. He
has served as a committee member on the United States Food and Drug Administration Antiviral Drugs Advisory Committee and is a
member of the World Health Organization Global HIV Drug Resistance Network Steering Group. Dr. Schapiro is on the organizing and
scientific committee of international conferences on antiviral drug development, clinical pharmacology and resistance, as well
as contributing to guidelines publications. His research has appeared in major journals such as Lancet and Annals of Internal Medicine.
He has served on the scientific advisory boards of major pharmaceutical and molecular diagnostic companies and has been involved
in the development of multiple antiviral drugs over the last 20 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Schapiro has devoted his career to HIV clinical care, research
and education since completing his Fellowship in Infectious Diseases and Geographic Medicine at Stanford University School of Medicine,
Stanford CA. He graduated from the Ben Gurion University School of Medicine and completed his Medical Residency at the Rabin Medical
Center in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;I am very excited to be joining the Board of XTL and
helping develop their hCDR1 asset which has shown some encouraging safety and preliminary efficacy data in previous clinical trials&rdquo;
he said. &ldquo;Safe and efficacious drugs remain an important unmet medical need for the large numbers of patients suffering from
SLE worldwide. Preclinical as well as clinical data generated thus far suggest this asset is one of the most promising treatments
for lupus at this stage of development&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Dobroslav Melamed, 37, is a biotech entrepreneur with over
10 years of experience in the life science industry. He has demonstrated success in taking drugs from the lab to the shelf by
identifying target markets, planning regulatory strategy, raising capital, executing successful clinical trials and scaling up
to commercial production. He is currently establishing two companies involved in the development of a treatment for Ebola and
novel drug delivery. Until September 2014, he was the President of SciVac (formerly SciGen IL), a high growth biopharmaceutical
company that develops, manufactures and markets recombinant human health care biotechnology derived products, including vaccines.
Dr. Melamed was responsible for SciVac&rsquo;s operations, clinical trials and new business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Melamed is the co-founder of Periness LTD, a developer of
new drugs for male infertility and Oshadi LTD, a developer of oral carriers for proteins like insulin. He has also been a researcher
at Bar-Ilan University&rsquo;s Male Fertility clinic, where he assisted in the development of new drugs for male infertility; and
QBI, where he worked in the Pre-clinical and Research Pharmacology Department establishing In Vivo models for drug discovery and
delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Melamed earned a PhD in Biotechnology and a Bachelor of Arts
degree in Biotechnology from the Bar-Ilan University, Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;I believe that XTL&rsquo;s clinical assets offer a unique
opportunity to treat significant unmet medical needs in lupus and multiple myeloma&rdquo; stated Dr. Melamed. &ldquo;I look forward
to being involved in successfully developing these assets together with the XTL Bio management team.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About XTL Biopharmaceuticals Ltd. (&ldquo;XTL&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">XTL
Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical
products for the treatment of unmet clinical needs. XTL is focused on late stage clinical development of drugs for the treatment
of lupus and multiple myeloma. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">XTL
is a public company traded on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTL). XTL shares
are included in the following indices: Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white"><B>Cautionary
Statement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">Some
of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties.
For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. Please see the risk factors associated with an investment in our ADSs or ordinary shares which are
included in our Annual Report on Form 20-F as filed with the U.S. Securities and Exchange Commission on April 2, 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Investor Contacts:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">Jeffrey
Goldberger / Garth Russell</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">KCSA
Strategic Communications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">Phone:
212-896-1249 / 212-896-1250</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">Email:
jgoldberger@kcsa.com</FONT><FONT STYLE="background-color: white"> / grussell@kcsa.com</FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``U`+`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W)M1L8V*O
M=P*RG!4R`$'\ZR/$^NBP\+:A>Z?-'+/$@"E&#;"Q`S^&<_A7'_%#PKNA&NV4
M85D^6Y5!C<#T?Z]C^'I7!^%]732=7!NE\VQN%,%U&W(:-NOY=?PKUL-@(5*2
MK1E>W2W;H>7B,;.G4=*2M?K^I236=2CO_MRWUP+K.?-\P[C^-?06BZU'=Z#8
M7E[-#!/<0+(RLX7)QR0#VKD#\,/#UL[:C+>W!L44S%"PV[<9^]Z8_&O,_$6L
MG6M8EN57R[=0(K>(<".->%'^?6NRI"EF#2IZ<N[M^!RTY5,$FYZWZ7_$^BXK
M^TF<)%=0N_\`=60$TS^U-/\`^?VV_P"_J_XUPWPY\*G3]';5+I"+NZ3]TK#F
M.,CC\3U^F*\N.@:UD_\`$JU#_P`!W_PK@I8&C4J3A[32/X_B=E3&5:<(R<-S
MZ+_M33_^?VV_[_+_`(T?VII__/[;?]_E_P`:^;+G3=1L8Q)=V5S;HQVAI8F4
M$^G(J*W@N;R80VT4LTIZ)&I8G\!74LGIM7]IIZ?\$Y_[5FG;D_'_`(!]+_VK
M8?\`/];_`/?U?\:7^U=/_P"?VV_[^K_C7SE_8&M_]`K4/_`=_P#"J4L<L$K1
M3(\<B'#(X((/H0:(Y13E\-3\/^"#S2HMX'U##-%.F^&19$_O*P(_2I.]<9\+
MO^1)@_Z[2?\`H5=I7C5J?LZDH=F>M2J>TIJ?="$@#G@"H(;N"<E8IHW8<X5@
M32W?_'G-_N-_*O+_`(:9.OW'.?\`1S_Z$M72H\].4[_"<U?%.E6A2M?FN>L4
M445@=I&[K&A=V"J.22<`5'%<03@^5-'(!UV,#C\JJ:[9RZCHEW:0[?-FC*KN
M.!FN?\%>&]0T![QKXQ'S@@7RW+=,Y[>]:QA!TW)RU70YIU:D:T8*%XO=]CLZ
M***R.D****`()X8[F"2"5`\<BE75AP0>"*^>/%WAZ3PWKDMI@FW?YX'/\2'^
MHZ&OHS/2N!^*J:<WAI'NCBZ67_1MO4G^(?3'7WQ7H99B)4JRATE_5SS\PHQJ
M4G+JCSJX\9WD_@V'P^VX;'PTN?O1#E4_/]`*L>`/"Y\0ZR)ITS8VQ#RYZ.>R
M?CW]OK7('UKWSX=2:=)X/MET_P"4J2)P?O>9WS^F/;%>QCI_5:#]DK<S_/J>
M9@X_6*R]H]E^1UZ@```8`[4N!Z445\N?1GG/Q@_Y%RS_`.OL?^@-7%?#'_D>
M;/\`ZYR?^@&NU^,'_(N67_7V/_0&KBOAC_R/-G_USD_]`-?087_D73^9X6(_
MWZ/JCWK`]*^</&/_`"..K?\`7P_\Z^CZ^</&/_(X:M_U\O\`SKGR7^-+T_4W
MS;^''U/6_A;_`,B1!_UVD_\`0J[2N+^%O_(D0?\`7:3_`-"KM*\_&?QY^K.[
M"_P(>B(+O_CTF_ZYM_*O'/"&M6^@WMU=S@M^X*HB]6;(X]J]CN_^/2?_`*YM
M_*O&?!VE)JOB.&*9=T48,KJ>X'0?GBNG!\OLJG/MH>7FCG]8I>S^+6QN-KOC
M74E^U6MO+%!U41P#!'MD$FK&C_$"[@O19Z["%&=IE";&0_[0_P#U5Z.!M&`*
MX#XEZ9&;.WU)$Q*C^6[`=5(XS]"/UI4ZM*K+V<H))]MQUZ&(PT'7C4<FMT]F
M==K.H/8Z'=7]OL=HHRZ9Y4_E6)X+\37OB%KP7<<""$(5\I2,YSG.2?2LS3;]
M[WX77BR'+01O%GU`P1^AQ^%5OA<P5M5)Z!8R?_'J7U>,:,[K5,KZW.>(I<KM
M&2NU\F=/XD\66GAZ,1L/-O'7*0@XX]6/85R,?B'QIJR^?90,D7.#'"-I^A;.
M:S=,B_X2WQJSW()B=VE=2?X!T7^0KU]$6-`JJ%4#&`,`"B7L\,E'E4I/>Y-)
MUL=*4U-Q@G96W?F>=V/C[4+"]^RZ]:%1W8)L=?<CN/RKT*">.Z@CGA8/%(H9
M&'<$9!KFO'.D0ZAH,MSL`N+53(C@<X'WA],<_A5/X;Z@]SHLUG(26MI/ER>B
MMR!^8:HJPA4H^U@K-;HVP]2K0Q'U>K+F35T^OHSLIIX[>!YIG"1HI9F8X``Z
MFOGKQAXDD\3:[)<`D6L?[NW0]E]?J>O_`.JNU^*/BQ1'_8-E("6YNF4],'A/
MZG\/>N.\$^'&\1>((X9%/V.#$EP?]GLOXGC\_2O2R^A&A2>)J_+T_P""8XZL
MZU14*?\`3_X`ZY\&WUMX,@UYL_.^6BQRL1X5_P`3^A%.\"^*&\-ZXIF8_8KC
M"3KZ>C?A_+->]3V<%Q926<L:M!(AC9,<;2,8KYS\2Z'+X>UVXL),E%.Z)S_&
MAZ'_`#W!K7"8I8V,Z57^E_P#/$X9X64:L/Z?_!/I%75T#*05(R"#P13Z\W^%
M_BG[;9_V)=R9N+=<PL3]^/T^H_E]*](KP:]&5&HZ<NA[-"LJT%-'G7Q@_P"1
M<LO^OH?^@-7%?#'_`)'FS_ZYR?\`H!KM?C!_R+EE_P!?8_\`0&KBOAC_`,CS
M9_\`7.3_`-`->UA?^1=/YGDXC_?H^J/>J^</&/\`R.&K?]?+_P`Z^CZ^</&/
M_(X:M_U\O_.L,F_C2]/U-\V_AQ]3UKX6_P#(D0?]=I/_`$*NUKYRTOQEKNC6
M2V6GWODVZDL$\I&Y/7D@FKO_``LCQ7T_M/\`\@1__$U6(RNM4JRFFK-^?^1%
M',J5.G&#3T1[Q=_\><P_Z9M_*O+OAHZCQ#.I."UN<#UY%<Q_PL3Q3("C:GE6
MX(\B/I_WS5C1)K^QNSJ5C$7-K@R#MM/!S[4XX&I1I3A-KWCBQ6.A/$4JD4_=
MO<]VZ]:Y+XBS"/PNT9/,LJ*H^G/]*C@^(NC26X:<30R8^:/;NY]C_P#JKDM;
MU:\\:ZM#:V%N_D(<1(>O/5F/;^E<6'PU2-52FK):G;C<=2G0<*;YI2T27F:N
M@Q-'\,=5D*D"0R,">X``_I3/AM&98=9C'!:)%'X[ZZ?5+"/2_`-U91G*PVI4
MGU/<_GFN=^%OW]4^D7_LU;.IST:DUW_R.94?9XJA3?2+_)F3\/F$/BORW.UV
MA9`#W/!Q^AKUW->6>+-'O=`U[^VK!6$+R>:'49\MSU!]C_7%=!8?$729;=6O
M!+;S`?,H0LI/L1_6HQ4)5[5::NFC3`5X87FP]9\K3TOLT;WB21(/#6I.YP/L
M[J/J1@?J:Y'X6Q,L>IS$?([1*#[C=G^8K,\4>*I?$C1Z9I4,GDNPSQ\TK=A@
M=O\`/:N\\+:/_8V@P6S<3,/,F_WSU'X<#\*B471P[C+>3V-*<UBL:JE/6,$]
M>[8V3P?X>EE:232;9G8EF9ER23U-7M/TG3](1TL+.*W5SN<1KC<?>BBN%UJD
MXVE)L]>-&FG=(T*S=1T'2]6=7O[*&X9!A3(N2!113C)Q=XNP2BI*TD5[7PKH
M=E=)<6VF6\4T7*NBX(-;7:BBG*4I/WG<481BO=11U'2K'5X5BO[:.XC1MRK(
M,@'&,_K56Q\-:-IUTMS::=!#.F=KHN",C!HHI1J34+7T)E"+G>QL=:Q+GPGH
M-W<O<3Z7;R32,6=V3DD]Z**<92B_==BI0C)>\KD?_"&>&_\`H#VO_?-'_"&^
M&_\`H#VO_?-%%7]8K?SO[V+ZO2_E7W"CP9X<SD:/:_\`?%7K71].L&=K2R@A
M+##%$`R/0T45FZU22]Z3?S&J%)/2*^XH7/@[0+V8R2Z<@8_W&9!^2D"M*RTR
MSTV'R[.WCA3T1<9^OK1114J3Y;7%'#THRO&*3]">Y@BN8&@GC62)QAE;H156
MPTJQTTR&SMHX=^-VP8SCI111&3Y;#E"+FG8O.BLA5@"#U!%8-SX.T"[EWRZ;
M&&_Z9LT8_)2!1150DX[,)4:=1>_%/U-#3M&T_3%Q9VL46>I5>3]3U-:%%%3)
*MO4<81@K15C_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
